“Genomenon Curate-Pro is a natural extension of Genomenon’s vision of curating the genome – leveraging the company’s genomic curation technology and human expertise to deliver an on-demand service to our clinical customers,” explained Genomenon CEO, Mike Klein. “With Curate-Pro, Genomenon takes on the back-end research and curation of clinical evidence to ACMG clinical guidelines, allowing our customers to focus on higher value-added patient-facing activities.”
Genomenon recently announced its curation of the clinical exome at the gene level with more than 5,500 genes and 9,000 disease-gene relationships curated to ClinGen standards, all provided on its Mastermind Genomic Intelligence Platform. Curate-Pro will deliver the same high-quality curated evidence available in Mastermind on a customized basis for germline variant curation on-demand.
In addition to Curate-Pro, the company also announced the launch of Genomenon Interpret which connects clients with a member of Genomenon’s team of genomic scientists as an extension of their own teams. Genomenon Interpret works within clients’ existing workflows and SOPs.
More Information on Genomenon’s curation services may be found at https://www.genomenon.com/curation-services/
About Genomenon:
Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and curation and consulting services.
Contact:
Colleen McMillen
[email protected]
SOURCE Genomenon
